Technical Analysis for ARRY - Array BioPharma Inc.

Grade Last Price % Change Price Change
grade B 14.83 0.82% 0.12
ARRY closed down 1.22 percent on Wednesday, November 14, 2018, on 81 percent of normal volume. It ran into resistance at its 50 day moving average.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Flat Down
See historical ARRY trend table...

Date Alert Name Type % Chg
Nov 14 50 DMA Resistance Bearish 2.06%
Nov 14 Down 3 Days in a Row Weakness 2.06%
Nov 14 Down 4 Days in a Row Weakness 2.06%
Nov 13 Fell Below 50 DMA Bearish 0.82%
Nov 13 MACD Bearish Signal Line Cross Bearish 0.82%
Nov 13 Down 3 Days in a Row Weakness 0.82%
Nov 12 Fell Below 200 DMA Bearish -1.79%
Nov 12 Fell Below 20 DMA Bearish -1.79%
Nov 12 Stochastic Sell Signal Bearish -1.79%
Nov 12 Overbought Stochastic Strength -1.79%

Older signals for ARRY ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases primarily in North America, Europe, and the Asia Pacific. Its proprietary clinical programs include ARRY-520, a kinesin spindle protein inhibitor, which is in Phase 2 clinical trial for patients with multiple myeloma; ARRY-614, a p38/Tie2 dual inhibitor that is in Phase 1 clinical trial for the treatment of myelodysplastic syndromes; ARRY-797, a p38 inhibitor, which is in Phase 2 clinical trial for pain; and ARRY-502, a CRTh2 antagonist that is in Phase 2 clinical trial for asthma. The company's partnered clinical programs comprise drug candidates for the treatment of cancer, including MEK162, an MEK inhibitor in Phase 3 clinical trial; Selumetinib, an MEK inhibitor in Phase 2/pivotal clinical trial; and GDC-0068 AKT inhibitor, LY2606368 Chk-1 inhibitor, and VTX-2337 toll-like receptor in Phase 2 clinical trial. Its partnered clinical programs also include Danoprevir, a Hepatitis C virus protease inhibitor in Phase 2 clinical trial; ARRY-543/ASLAN001, a HER2/EGFR inhibitor for gastric cancer in Phase 2 clinical trial; GDC-0575 and GDC-0425 Chk-1 inhibitors for cancer in Phase 1b clinical trial; ARRY-380, an HER2 inhibitor in Phase 1 clinical trial for breast cancer; and GDC-0994 in a Phase 1 dose-escalation study in patients with locally advanced or metastatic solid tumors. The company has collaborations with Amgen Inc.; ASLAN Pharmaceuticals Pte Ltd.; AstraZeneca, PLC; Celgene Corporation; Eli Lilly and Company; Genentech Inc.; Novartis International Pharmaceutical Ltd.; Oncothyreon Inc.; and VentiRx Pharmaceuticals, Inc. for the development and commercialization of the partnered drugs. Array BioPharma Inc. was founded in 1998 and is headquartered in Boulder, Colorado.
Is ARRY a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 1 bullish, 2 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 20.21
52 Week Low 10.36
Average Volume 2,696,037
200-Day Moving Average 15.8188
50-Day Moving Average 14.873
20-Day Moving Average 15.5415
10-Day Moving Average 16.203
Average True Range 0.9023
ADX 21.12
+DI 20.5333
-DI 25.8064
Chandelier Exit (Long, 3 ATRs ) 14.7631
Chandelier Exit (Short, 3 ATRs ) 16.3669
Upper Bollinger Band 17.6501
Lower Bollinger Band 13.4329
Percent B (%b) 0.26
BandWidth 27.13509
MACD Line 0.2356
MACD Signal Line 0.399
MACD Histogram -0.1634
Fundamentals Value
Market Cap 2.49 Billion
Num Shares 171 Million
EPS -0.72
Price-to-Earnings (P/E) Ratio -20.18
Price-to-Sales 41.12
Price-to-Book 153.97
PEG Ratio -1.06
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.63
Resistance 3 (R3) 15.72 15.45 15.44
Resistance 2 (R2) 15.45 15.17 15.40 15.38
Resistance 1 (R1) 14.99 15.00 14.86 14.90 15.32
Pivot Point 14.72 14.72 14.65 14.67 14.72
Support 1 (S1) 14.26 14.44 14.13 14.17 13.74
Support 2 (S2) 13.99 14.27 13.94 13.68
Support 3 (S3) 13.53 13.99 13.62
Support 4 (S4) 13.44